Novartis‘ CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
“The longer-term implications are significant,” CEO Vas Narasimhan told CNBC’s Carolin Roth.
Novartis is focused on getting European and Japanese governments to quickly change how they reward innovation, he said, adding that if this doesn’t happen, then novel medicines might see delayed entry into these markets and patients won’t have access to the drugs.
“The reality of MFN is going to set in in the next 18 months.”
This is breaking news. Please refresh for updates.
Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.